Key factors
sym | OCGN |
exch | US |
MCap | 259.06M |
Beta | 3.68 |
EPS | -0.32 |
Div date | 0000-00-00 |
Yesterday
sym | OCGN |
exch | US |
close | 1.78 |
50 Day MA | 0.678 |
200 Day MA | 0.512 |
52 Week High | 1.28 |
52 Week Low | 0.345 |
Target Price | 6.33 |
Market Cap Mln | 259.06 |
Share statistics
Shares Outstanding | 256.50M |
Shares Float | 252.37M |
Percent Institutions | 10.34 |
PercentInsiders | 1.452 |
SharesShort | 24.36M |
Short Ratio | 10.87 |
Shares Short Prior Month | 23.70M |
Short Percent | 12.31 |
Income
Revenue TTM | -380.0 |
Gross Profit TTM | -49.7M |
EBITDA | -80.3M |
Diluted Eps TTM | -0.32 |
earning
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Current Year | -0.28 |
EPS Estimate Next Quarter | -0.07 |
EPS Estimate Next Year | -0.28 |
Earnings Share | -0.32 |
Dividend
Dividend Date | 2019-09-30 |
Last Split Date | 2019-09-30 |
Last Split Factor | 1:60 |
business
Enterprise Value Ebitda | -2.63 |
Enterprise Value Revenue | 35591 |
Book Value /share | 0.228 |
Price Book MRQ | 4.436 |
Price Sales TTM | 25069 |
ReturnOnAssetsTTM | -0.53 |
ReturnOnEquityTTM | -0.98 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US67577C1053 |
CIK | 1372299 |
Code | OCGN |
CUSIP | 67577C105 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-03-08 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 15.22 |
Full Time Employees | 84.0 |
IPODate | 2014-12-03 |
MostRecent Quarter | 2023-09-30 |
Contact
Name | Ocugen Inc |
Address | 263 Great Valley Parkway, Malvern, PA, United States, 19355 |
Country Name | USA |
Phone | 484 328 4701 |
Web URL | https://www.ocugen.com |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.